Dallas, TX (PRWEB) May 07, 2014
There has been a gradual increase in awareness of PCOS among the female population over the years. The acceptability of PCOS drugs is expected to rise because of the increasing public awareness of the syndrome and the need to treat it. This is expected to result in increasing drug penetration. In the recent past, there have been several awareness and educational programs specifically targeting patients with PCOS. For instance, September is celebrated annually as PCOS Awareness Month by the PCOS Foundation. The aim of the PCOS Foundation is to spread awareness through public and professional education programs to improve diagnosis and eliminate the lifetime risks associated with PCOS. The PCOS Foundation hosts a PCOS Awareness 5K Fun Run every September, which acts as part of the awareness campaign and encourages media discussion about PCOS. Thus, the increasing awareness and resultant higher treatment-seeking rates for PCOS are expected to contribute to the growth of the market.
According to the report, the Global PCOS Drugs market is driven by several factors, of which an increase in the number of patients is one of the major drivers. Co-morbid conditions such as diabetes, obesity, and other cardiovascular complications lead to an increase in the number of PCOS patients.
This report covers the present scenario and the growth prospects of the Global PCOS Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of marketed, off-label, and generic drugs used in the treatment of PCOS.
Global PCOS Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PCOS Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Purchase Report @ http://www.sandlerresearch.org/purchase?rname=16794.
- Bristol Myers Squibb Co.
- Merck & Co. Inc.
- Novartis AG
- Sanofi SA
- Teva Pharmaceutical Inc.
Other Prominent Vendors
- AstraZeneca plc
- Catalysis SL
- Crinetics Pharmaceuticals Inc.
- Dexa Medica Group
- EffRx Inc.
- Neurocrine Biosciences Inc.
Over the years, there has been a gradual increase in awareness about PVA. The acceptability of PVA drugs is expected to rise during the forecast period because of increasing public awareness about PVA and the need for treatment. This is expected to result in increasing drug penetration. The growth witnessed during the past was primarily because of the growing awareness among patients and physicians, which resulted in increased diagnosis and treatment rates. In the recent past, there have been several awareness and educational programs specifically targeting patients with PVA. For instance, Novo Nordisk, one of the prominent players of this market introduced the formation of GLAM to ignite the conversation on vaginal health in 2013. GLAM is basically an alliance that encourages women to discuss issues about the menopause and seek help. Thus, the increasing awareness and resultant higher treatment seeking rates for PVA are expected to contribute to the growth of the market during the forecast period.
According to the report, the Global PVA Drugs market has substantial unmet needs. Currently, the market is not well served with the existing product options; therefore, there exists a significant opportunity for new vendors to capitalize on the market. The market has significant unmet needs in terms of low diagnosis rates, low levels of treatment seeking behavior among menopausal women, and safety concerns associated with ERT. Efficient and safe treatment options to meet the current demand are in the pipeline. Hence, there is huge potential for new entrants to grow by addressing the high unmet need of the market.
Further, the report states that the patent expiries of major approved drugs will affect the market adversely and will slow down its growth during the forecast period. The shift toward lower priced drugs will lead to a drop in the market valuations for that drug, reducing the overall market value. The introduction of these low-cost drugs is likely to increase the competition in the market, thereby eventually reducing the price of key drugs.
- Actavis plc
- Novo Nordisk A/S
- Pfizer Inc.
- Shionogi & Co. Ltd.
Other Prominent Vendors
- ANI Pharmaceuticals Inc.
- Bionovo Inc.
- EndoCeutics Inc.
- QuatRx Pharmaceutical Co.
- PeP-Tonic Medical AB
- Teva Pharmaceutical Industries Ltd.
- Therapeutics MD Inc.
- Upsher-Smith Laboratories Inc.
Purchase Report @ http://www.sandlerresearch.org/purchase?rname=16810.
Sandlerresearch.org (http://www.sandlerresearch.org/) is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.